Pulmonary hypertension significantly affects patients’ quality of life. A review of published literature and clinical trials in pulmonary hypertension was conducted by the authors of this study to identify and evaluate patient-reported outcome measures (PROMs) that assess pulmonary hypertension-specific HRQoL for use in clinical studies. To assess treatment benefits and patient experiences, various PROMs were evaluated. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), emPHasis-10, Living with Pulmonary Hypertension Questionnaire (LPHQ), and Pulmonary Arterial Hypertension—Symptoms and Impact (PAH-SYMPACT), were reviewed for their validity, psychometric properties, and feasibility. Each PROM had strengths and weaknesses, and no single PROM was recommended for all situations. Optimal selection depends on the study’s purpose. The authors of the study conclude that recommendations should be considered as a snapshot of a quickly evolving landscape and should be updated as new information emerges.
Read the full article at this link on the CHEST website
Citation
Yaron Yarlas, Stephen C. Mathai, Steven D. Nathan, Hilary M. DuBrock, Kellie Morland, Natalie Anderson, Mark Kosinski, Xiaochen Lin, Peter Classi, Considerations When Selecting Patient-Reported Outcome Measures for Assessment of Health-Related Quality of Life in Patients With Pulmonary Hypertension: A Narrative Review, Chest, Volume 162, Issue 5, 2022, Pages 1163-1175, ISSN 0012-3692, https://doi.org/10.1016/j.chest.2022.08.2206.